SLU-PP-332 Explained: The 'Exercise Mimetic' ERR Agonist
SLU-PP-332 is a synthetic pan-ERR agonist that mimics endurance-exercise gene expression in animal models. Here's what's actually known, what's speculative, and why caution is warranted.
Published Jun 14, 20264 min read
SLU-PP-332 is a synthetic pan-ERR (estrogen-related receptor) agonist developed by researchers at Saint Louis University. In rodent studies it produces gene-expression and metabolic changes resembling those induced by endurance exercise — increased fatty-acid oxidation, mitochondrial biogenesis, and improved running endurance. No human trials have been published. The community-driven enthusiasm currently far outpaces the evidence base; caution is warranted.
For the per-peptide research profile, see SLU-PP-332. For the broader metabolic-peptide landscape, see /peptides/category/metabolic.
What it is
SLU-PP-332 (full name: a substituted phenoxyacetic acid analogue) is a synthetic small molecule that activates all three ERR receptor isoforms (ERRα, ERRβ, ERRγ). The ERR receptors are nuclear receptors that regulate transcription of genes involved in mitochondrial biogenesis, fatty-acid oxidation, and oxidative phosphorylation — the gene-expression programs normally upregulated by endurance training.
Strictly speaking, SLU-PP-332 is a small molecule, not a peptide. It's discussed in the peptide community because it's distributed through the same research-chemical channels and used for similar body-composition / performance goals as MOTS-c, AICAR, and the metabolic-peptide class.
What the published research shows
The headline result is from a 2023 paper in the journal PNAS (Billon et al., PNAS 2023): mice given SLU-PP-332 ran ~50% farther on a treadmill than untreated controls, with parallel increases in mitochondrial-biogenesis gene expression in skeletal muscle.
A 2024 follow-up extended the metabolic-effect characterization: obese mice on SLU-PP-332 lost weight on a high-fat diet without changing food intake, primarily through increased energy expenditure.
These are interesting and mechanistically plausible. They are also entirely rodent data.
What's not yet known
- Human bioavailability. Pharmacokinetics in humans have not been published.
- Human dosing. No human-equivalent dose has been established; community dosing protocols are translations from rodent doses based on body-weight ratios, which is not how pharmacology actually works.
- Human safety profile. No published human safety data of any kind.
- Long-term effects. ERR receptors are involved in basic cellular energy regulation; chronic pan-agonism may have unexpected effects in heart, liver, or other high-energy tissues.
- Off-target activity. The selectivity profile of SLU-PP-332 outside the ERR family is incompletely characterized.
Why the enthusiasm
The phrase "exercise mimetic" makes for compelling headlines. The PNAS paper showed clear, large effects on mouse exercise endurance with a single oral compound. If those effects translate to humans, SLU-PP-332 would be a meaningful tool for:
- People who can't exercise due to injury or disability.
- Endurance athletes (though this is also why anti-doping agencies are watching it).
- Metabolic-disease patients.
- Body-composition use cases.
"If those effects translate" is the unresolved word.
How it compares to other metabolic peptides
| SLU-PP-332 | MOTS-c | AICAR | Tesamorelin | |
|---|---|---|---|---|
| Class | Small molecule (not peptide) | Peptide | Nucleoside | Peptide (GHRH) |
| Mechanism | Pan-ERR agonist | Mitochondrial peptide | AMPK activator | GHRH agonist |
| Human evidence | None published | Limited | Limited human pharma use | Strong (FDA approved for HIV lipodystrophy) |
| Route | Oral in rodent studies | Injection | Injection or oral | Injection |
| Status | Research compound, no clinical trials | Research peptide | Some clinical use (cardioprotection) | FDA approved |
The closest published precedent for "exercise mimetic" is AICAR — also rodent-data-strong, also community-popular, but with a much longer human-use history and a clearer safety read.
Practical guidance
For users considering SLU-PP-332:
- Acknowledge the evidence ceiling. This is rodent-data-only. The clinical-translation rate of rodent exercise-mimetic findings is low — many compounds that worked in mice have not worked in humans.
- Sourcing risk is elevated. Research-chemical channels have variable quality control; for a compound with no clinical precedent, product-quality and dose-accuracy risk compound the unknown-mechanism risk.
- No defensible dose. Rodent doses do not scale linearly to humans. Any human dose is speculation.
- No way to monitor for the unique risks. Standard labs don't capture ERR-axis perturbation.
- Anti-doping. Competitive athletes — SLU-PP-332 is on WADA's monitoring list for potential prohibition.
The defensible position right now is: interested observer, not user, until human Phase 1 / Phase 2 data exists.
What would change the calculus
The picture shifts meaningfully if:
- A human Phase 1 trial publishes (pharmacokinetics + acute safety).
- A small human Phase 2 trial reads positive (efficacy signal + tolerability).
- WADA either prohibits it (clarifies the competitive-athletics question) or formally clears it.
- Regulatory clarity emerges on research-chemical distribution.
None of these have happened as of mid-2026.
Where to go from here
- SLU-PP-332 research profile with study citations.
- /peptides/category/metabolic — full metabolic-peptide hub.
- /peptides/category/energy — energy / performance hub.
- Are peptides safe?, peptide side effects — safety frame.
This is an informational summary of published research, not medical advice. SLU-PP-332 has no human clinical-trial data and no approved medical use.